News NFL Biosciences

Equities

ALNFL

FR0014003XT0

Market Closed - Euronext Paris Other stock markets 09:05:04 03/05/2024 pm IST			5-day change	1st Jan Change
1.79 ^EUR	-2.72%		-1.65%	+24.31%

12/04	Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin...
12/04	NFL Biosciences: successful capital increase	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NFL Biosciences : further strengthens its operational team with the arrival of a Head of Development and Manufacturing	18/04	PU
NFL Biosciences : renforce son équipe opérationnelle avec l’arrivée d’une Responsable du développement et de la fabrication	18/04	PU
Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin...	12/04
NFL Biosciences: successful capital increase	12/04	CF
NFL Biosciences Raises EUR3 Million for Clinical Trial, Partnerships	12/04	MT
NFL Biosciences : Successful capital increase for NFL Biosciences with over €3 million raised	12/04	PU
NFL Biosciences : launches a fundraising round for 3 million euros through a capital increase	11/04	PU
NFL Biosciences : lance une levée de fonds d’environ 3 millions d’euros par voie d’augmentations de capital	11/04	PU
NFL BIOSCIENCES : SHOWCASES THE RESULTS OF ITS STUDIES TO THE SCIENTIFIC AND PHARMACEUTICAL COMMUNITIES	02/04	PU
NFL BIOSCIENCES : VALORISE SES RÉSULTATS D’ÉTUDES AUPRÈS DE LA COMMUNAUTÉ SCIENTIFIQUE ET PHARMACEUTIQUE	02/04	PU
NFL BIOSCIENCES : ACTIVITÉS & RÉSULTATS ANNUELS 2023	29/03	PU
NFL BIOSCIENCES: 2023 FULL-YEAR BUSINESS AND EARNINGS UPDATE	29/03	PU
NFL BIOSCIENCES: INITIATION OF ANALYST COVERAGE BY PORTZAMPARC - BNP PARIBAS GROUP	11/03	PU
NFL Biosciences: success of smoking cessation study	30/01	CF
NFL Biosciences : PRE-IND application filed with the FDA in the United States for NFL-301, indicated for reducing alcohol consumption	19/12	PU
NFL BIOSCIENCES : DÉPÔT D’UNE DEMANDE DE PRE-IND AUPRÈS DE LA FDA AUX ÉTATS-UNIS POUR NFL- 301 DÉDIÉ À LA RÉDUCTION DE LA CONSOMMATION D’ALCOOL	19/12	PU
NFL BIOSCIENCES: PRE-IND APPLICATION FILED WITH THE FDA IN THE UNITED STATES FOR NFL-301, INDICATED FOR REDUCING ALCOHOL CONSUMPTION	19/12	PU
NFL BIOSCIENCES: 2023 FIRST-HALF BUSINESS AND EARNINGS UPDATE	05/23/05	PU
NFL Biosciences : Promising results of the PRECESTO clinical trial revealing a prolonged effect for NFL-101 and modification of the strategy for communicating the CESTO II study results	25/23/25	PU
NFL BIOSCIENCES: PROMISING RESULTS OF THE PRECESTO CLINICAL TRIAL REVEALING A PROLONGED EFFECT FOR NFL-101 AND MODIFICATION OF THE STRATEGY FOR COMMUNICATING THE CESTO II STUDY RESULTS	25/23/25	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News NFL Biosciences

Equities

ALNFL

FR0014003XT0

Summary

Filters